Strain Data Sheet

RBRC01477

Strain Information

Image
BRC No.RBRC01477
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6.129S6-Ptprj<tm1Taka>/SataRbrc
Former Common nameCD148/DEP-1 KO/PTPRJ, CD148 KO
H-2 Haplotype
ES Cell line
Background strain
Appearanceblack [a/a B/B C/C]
Strain developmentDeveloped by Dr Takamune Takahashi at Vanderbilt University Medical Center in 2003. A targeting construct containing EGFP and neo was transfered into ES cells to disrupt Ptprj gene. GFP fluorescence was not detected in mutant mice.
Strain descriptionB6.129S6-Ptprj<tm1Taka>. Protein tyrosine phospatase, receptor type J (CD148) is a member of the receptor tyrosine phosphatase family playing an important role in cell growth, differentiation, and development. Homozygous Ptprj<tm1Taka> mutant mice were embryonic lethal due to abnormal cardiovascular system morphology.
Colony maintenanceBackcross to C57BL/6 (Heterozygote x C57BL/6JJcl)
References
A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development.
Takahashi T, Takahashi K, St John P L, Fleming P A, Tomemori T, Watanabe T, Abrahamson D R, Drake C J, Shirasawa T, Daniel T O
Mol. Cell. Biol., 23, 1817-1831 (2003). 12588999

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
GFP Green Fluorescent Protein (Aequorea victoria)2
Ptprj
MGI:104574		protein tyrosine phosphatase receptor type J2Ptprj<tm1Taka>
MGI:2653313		targeted mutation 1, Takamune Takahashi
  • colorectal cancer(MedGEN)
    • loxP phage P1 loxP2loxP
    loxP phage P1 loxP2loxP
    neo neomycin resistance gene (E. coli)2 herpes simplex virus thymidine kinase promoter (HSV tk promoter)
    SV40 polyA2

    Phenotype

    Phenotype annotation from literatures by Mammalian phenotype ontology
  • abnormal dorsal aorta morphology (MP:0004787)

  • abnormal endocardium morphology (MP:0003974)

  • abnormal heart development (MP:0000267)

  • abnormal intersomitic vessel morphology (MP:0012253)

  • abnormal myocardial trabeculae morphology (MP:0002189)
    • more 21 phenotypes
  • abnormal pericardial cavity morphology (MP:0012501)

  • abnormal pericyte morphology (MP:0003719)

  • abnormal vascular branching morphogenesis (MP:0003227)

  • abnormal vascular development (MP:0000259)

  • abnormal vascular endothelial cell morphology (MP:0006055)

  • abnormal vascular smooth muscle morphology (MP:0005592)

  • abnormal vitelline vascular remodeling (MP:0004076)

  • abnormal vitelline vasculature morphology (MP:0003229)

  • absent atrioventricular cushions (MP:0000298)

  • decreased embryo size (MP:0001698)

  • delayed heart looping (MP:0009328)

  • distended pericardium (MP:0000292)

  • embryonic growth retardation (MP:0003984)

  • embryonic lethality during organogenesis, complete penetrance (MP:0011098)

  • embryonic lethality during organogenesis, incomplete penetrance (MP:0011108)

  • enlarged pericardium (MP:0000291)

  • failure of vascular branching (MP:0000264)

  • increased vascular endothelial cell number (MP:0006056)

  • microcephaly (MP:0000433)

  • thin myocardium (MP:0002652)

  • vascular smooth muscle hypoplasia (MP:0003814)
    • Detailed phenotype data

    Ordering Information

    Donor DNAJellyfish GFP cDNA, SV40 polyA, Phage P1 loxP sites, herpes simplex virus thymidine kinase promoter (HSV tk promoter), E. coli neo, mouse Ptprj (CD148) genomic DNA
    Research applicationCre/loxP system
    Fluorescent Proteins/lacZ System
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Mol. Cell. Biol., 23, 1817-1831 (2003). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT agrees to include the DEPOSITOR as a co-author in any publications resulted by the use of the BIOLOGICAL RESOURCE during the first 2 years after deposition by the DEPOSITOR to the RIKEN BRC.
    The RECIPIENT should contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
    DepositorMasanobu Satake (Tohoku University)
    Strain Statusan icon for Frozen embryosFrozen embryos
    an icon for Frozen spermFrozen sperm
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved sperm (within 1 month)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    No Data